These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 39163516)
1. Antisense Oligonucleotide Embedded Context Responsive Nanoparticles Derived from Synthetic Ionizable Lipids for lncRNA Targeted Therapy of Breast Cancer. Sarkar S; Moitra P; Bera S; Bhattacharya S ACS Appl Mater Interfaces; 2024 Sep; 16(35):45871-45887. PubMed ID: 39163516 [TBL] [Abstract][Full Text] [Related]
2. T7 Peptide-Conjugated Lipid Nanoparticles for Dual Modulation of Bcl-2 and Akt-1 in Lung and Cervical Carcinomas. Cheng X; Yu D; Cheng G; Yung BC; Liu Y; Li H; Kang C; Fang X; Tian S; Zhou X; Liu Q; Lee RJ Mol Pharm; 2018 Oct; 15(10):4722-4732. PubMed ID: 30138565 [TBL] [Abstract][Full Text] [Related]
3. Antisense Oligonucleotide-Conjugated Nanostructure-Targeting lncRNA MALAT1 Inhibits Cancer Metastasis. Gong N; Teng X; Li J; Liang XJ ACS Appl Mater Interfaces; 2019 Jan; 11(1):37-42. PubMed ID: 30548064 [TBL] [Abstract][Full Text] [Related]
4. Lipid Nanoparticles Loaded with an Antisense Oligonucleotide Gapmer Against Bcl-2 for Treatment of Lung Cancer. Cheng X; Liu Q; Li H; Kang C; Liu Y; Guo T; Shang K; Yan C; Cheng G; Lee RJ Pharm Res; 2017 Feb; 34(2):310-320. PubMed ID: 27896589 [TBL] [Abstract][Full Text] [Related]
5. LncRNA HOTAIR influences cell growth, migration, invasion, and apoptosis via the miR-20a-5p/HMGA2 axis in breast cancer. Zhao W; Geng D; Li S; Chen Z; Sun M Cancer Med; 2018 Mar; 7(3):842-855. PubMed ID: 29473328 [TBL] [Abstract][Full Text] [Related]
6. Targeting LncRNA Tian LI; Huang Y; Zhang B; Song YI; Yang L; Chen Q; Wang Z; Wang Y; He Q; Yang W; Yu S; Lu T; Liu Z; Gao K; Fan X; Song J; Zhai R Oncol Res; 2023; 31(4):463-479. PubMed ID: 37415734 [TBL] [Abstract][Full Text] [Related]
7. Correlating the Structure and Gene Silencing Activity of Oligonucleotide-Loaded Lipid Nanoparticles Using Small-Angle X-ray Scattering. Hammel M; Fan Y; Sarode A; Byrnes AE; Zang N; Kou P; Nagapudi K; Leung D; Hoogenraad CC; Chen T; Yen CW; Hura GL ACS Nano; 2023 Jun; 17(12):11454-11465. PubMed ID: 37279108 [TBL] [Abstract][Full Text] [Related]
8. Knocking Down Long Noncoding RNAs Using Antisense Oligonucleotide Gapmers. Maruyama R; Yokota T Methods Mol Biol; 2020; 2176():49-56. PubMed ID: 32865781 [TBL] [Abstract][Full Text] [Related]
9. Antisense oligonucleotides targeting lncRNA AC104041.1 induces antitumor activity through Wnt2B/β-catenin pathway in head and neck squamous cell carcinomas. Li M; Ding X; Zhang Y; Li X; Zhou H; Yang L; Li Y; Yang P; Zhang X; Hu J; Nice E; Wu H; Xu H Cell Death Dis; 2020 Aug; 11(8):672. PubMed ID: 32826863 [TBL] [Abstract][Full Text] [Related]
10. Long non-coding RNAs: From disease code to drug role. Chen Y; Li Z; Chen X; Zhang S Acta Pharm Sin B; 2021 Feb; 11(2):340-354. PubMed ID: 33643816 [TBL] [Abstract][Full Text] [Related]
11. Targeting long non-coding RNAs in cancers: progress and prospects. Li CH; Chen Y Int J Biochem Cell Biol; 2013 Aug; 45(8):1895-910. PubMed ID: 23748105 [TBL] [Abstract][Full Text] [Related]
12. Tips for Successful lncRNA Knockdown Using Gapmers. Lennox KA; Behlke MA Methods Mol Biol; 2020; 2176():121-140. PubMed ID: 32865787 [TBL] [Abstract][Full Text] [Related]
13. Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo. Yang L; Ma F; Liu F; Chen J; Zhao X; Xu Q Mol Ther Nucleic Acids; 2020 Mar; 19():1357-1367. PubMed ID: 32160706 [TBL] [Abstract][Full Text] [Related]
14. Application of a Quality-By-Design Approach to Optimise Lipid-Polymer Hybrid Nanoparticles Loaded with a Splice-Correction Antisense Oligonucleotide: Maximising Loading and Intracellular Delivery. Thanki K; Papai S; Lokras A; Rose F; Falkenberg E; Franzyk H; Foged C Pharm Res; 2019 Jan; 36(3):37. PubMed ID: 30623253 [TBL] [Abstract][Full Text] [Related]
15. LncRNA HOTAIR enhances breast cancer radioresistance through facilitating HSPA1A expression via sequestering miR-449b-5p. Zhang S; Wang B; Xiao H; Dong J; Li Y; Zhu C; Jin Y; Li H; Cui M; Fan S Thorac Cancer; 2020 Jul; 11(7):1801-1816. PubMed ID: 32374522 [TBL] [Abstract][Full Text] [Related]
16. In Vivo Administration of Therapeutic Antisense Oligonucleotides. Statello L; Ali MM; Kanduri C Methods Mol Biol; 2021; 2254():273-282. PubMed ID: 33326082 [TBL] [Abstract][Full Text] [Related]
17. Novel synthesized ionizable lipid for LNP-mediated P2X7siRNA to inhibit migration and induce apoptosis of breast cancer cells. Kiaie SH; Zangi AR; Sheibani M; Hemmati S; Baradaran B; Valizadeh H Purinergic Signal; 2024 Oct; 20(5):533-546. PubMed ID: 38436880 [TBL] [Abstract][Full Text] [Related]
18. Targeting Long Noncoding RNA with Antisense Oligonucleotide Technology as Cancer Therapeutics. Zhou T; Kim Y; MacLeod AR Methods Mol Biol; 2016; 1402():199-213. PubMed ID: 26721493 [TBL] [Abstract][Full Text] [Related]
19. A Combinatorial Library of Lipid Nanoparticles for RNA Delivery to Leukocytes. Ramishetti S; Hazan-Halevy I; Palakuri R; Chatterjee S; Naidu Gonna S; Dammes N; Freilich I; Kolik Shmuel L; Danino D; Peer D Adv Mater; 2020 Mar; 32(12):e1906128. PubMed ID: 31999380 [TBL] [Abstract][Full Text] [Related]